GlobalData on MSN2d
Zevra sells priority review voucher for $150m to support drug launches
Zevra has sold its US Food and Drug Administration (FDA) priority review voucher (PRV) for $150m to an undisclosed party. The ...
Zevra to Report 2024 Fourth Quarter and Full Year Financial Results
Company will host conference call on Tuesday, Mar. 11, 2025, at 4:30 p.m. ETCELEBRATION, Fla., Feb. 26, 2025 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a ...
FiercePharma2d
Arrowhead, Zevra fire up campaigns for Rare Disease Day 2025
Zevra used the awareness day to roll out the “Learn NPC, Read Between the Signs” disease awareness campaign. The biotech won ...
FiercePharma3d
Zevra to net $150M from priority review voucher sale tied to Miplyffa approval
For Zevra Therapeutics, last year’s approval of the rare lysosomal storage disorder drug Miplyffa appears to be the gift that ...
Zevra Therapeutics Enters Agreement to Sell its Rare Pediatric Disease Priority Review Voucher for $150 Million
LaDuane Clifton, Zevra’s Chief Financial Officer said, “This non-dilutive capital strengthens our balance sheet by adding gross cash proceeds of $150 million, supporting continued investment in our ...
Zevra Therapeutics launches new disease state awareness campaign
Zevra Therapeutics (ZVRA) announced, on Rare Disease Day, the launch of a new disease state awareness campaign, ‘Learn NPC, Read Between the ...
Zevra Therapeutics to Sell Priority-Review Voucher for $150 Million
Zevra Therapeutics has inked a deal to sell its Food and Drug Administration priority-review voucher to an undisclosed buyer for gross proceeds of $150 million.
Morningstar3d
Zevra to Report 2024 Fourth Quarter and Full Year Financial Results
CELEBRATION, Fla., Feb. 26, 2025 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on providing therapies for people living ...
Morningstar3d
Zevra Therapeutics Enters Agreement to Sell its Rare Pediatric Disease Priority Review Voucher for $150 Million
CELEBRATION, Fla., Feb. 27, 2025 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on providing therapies for people living ...
Nasdaq3d
Zevra Therapeutics Enters $150 Million Asset Purchase Agreement for Rare Pediatric Disease Priority Review Voucher
Zevra Therapeutics announces a $150 million sale of its Rare Pediatric Disease Priority Review Voucher to enhance its capital. Zevra Therapeutics, Inc. has announced the sale of its Rare Pediatric ...
MedCity News3d
Rare Disease Biotech Zevra Therapeutics to Sell FDA Drug Review Fast Pass for $150M
Zevra Therapeutics is still ramping up sales of its new FDA-approved drug, but the company has already found a way to cash in big on this therapy for a rare metabolic disorder. The priority review ...
The Pharma Letter3d
BRIEF—Zevra sells Miplyffa-linked PRV for $150 million
Rare disease-focused biopharma Zevra Therapeutics has agreed to sell its Rare Pediatric Disease Priority Review Voucher (PRV) to an undisclosed buyer for $150 million.